As antibody-based therapies continue to advance the treatment of cancer, autoimmune diseases, and infectious disorders, a parallel challenge has emerged: managing the immune system’s response to these biologics. Immunogenicity, tolerance breakdown, and unintended inflammatory reactions can compromise both the safety and efficacy of therapeutic antibodies. Amid this landscape, recent research on regulatory T cells (Tregs), the epitopes that activate them, known as Tregitopes, and antibody somatic hypermutation (SHM), intersect with immune tolerance mechanisms.
In a recent review, Tregitopes are described as short peptide sequences that bind to MHC class II molecules and stimulate natural regulatory T cells. These epitopes attenuate antigen-presenting cell activation, downregulate inflammatory signals like NF-κB, and promote the expansion of IL-10 and TGF-β-producing Tregs. They have shown promise in preclinical models of autoimmune diseases such as Guillain-Barré syndrome and inflammatory bowel disease, and have been explored in the context of vaccine design, enzyme replacement therapies (e.g., Pompe disease), and fetal-maternal tolerance. Crucially, Tregitopes act as immune silencers, restoring tolerance without broadly suppressing the immune system. Their immunomodulatory effects offer a tantalizing opportunity for antibody developers: incorporating or co-delivering Tregitopes could reduce the immunogenicity of monoclonal antibodies and extend their durability in vivo.
In naturally evolving antibody repertoires, however, a recent study addressing antibody somatic hypermutation (SHM) revealed that as antibodies mature and undergo SHM, Tregitope content is systematically depleted. This depletion was most pronounced in class-switched isotypes (IgG, IgA) and strongly correlated with SHM levels, suggesting that immune tolerance features are edited out during affinity maturation. Moreover, while Tregitopes and other potentially tolerogenic epitopes declined with SHM, T effector epitopes increased, potentially enhancing the risk of triggering effector T cell responses, such as those that drive immunogenicity against therapeutic antibodies. This has direct implications for antibody engineering, emphasizing the need to reintroduce Tregitopes or screen for epitope shifts during antibody lead optimization to retain immune tolerance features.
Meanwhile, researchers explored the specificity of Treg-mediated immune control, discovering that Tregs specific to the same self-peptides as pathogenic Tconv cells are essential for restraining autoimmunity, especially under inflammatory conditions such as infection-driven epitope mimicry. When Treg cells shared antigen specificity with self-reactive Tconv cells, they expanded earlier and more robustly, preventing harmful T cell proliferation and effector differentiation. Treg cell-mediated suppression is most effective when it is antigen-specific. For antibody therapies targeting self-antigens, engaging Tregs with matched specificity could be a strategy for reducing adverse effects and improving therapeutic outcomes.
While antigen-specific Treg activity is desirable, a more universal approach may also be feasible. A new preprint on α-tubulin-derived Tregitopes identified highly conserved sequences that mimic antigens from gut nematodes, capable of robustly inducing Foxp3+ IL-10-producing Treg cells. These peptides suppressed a broad range of immune responses, including class I and II antigen presentation, and promoted the differentiation of suppressive CD4+CD25^high T cells. In antibody therapeutics, such epitopes could be deployed to prevent the generation of anti-drug antibodies or to create tolerance scaffolds that accompany biologic delivery, especially in chronic use scenarios.
Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March).
Resistance to treatment continues to limit the long-term success of many therapies. In oncology, cancers may evade antibody-based treatments through mechanisms such as antigen loss, impaired intracellular trafficking, or suppression of immune responses. To address these challenges, researchers are d
Antibody-drug conjugates (ADCs) couple the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. Recent advances have been reported in both hematologic and solid tumors, with next-generation ADCs overcoming limitations of traditional therapies through improved t
Non–small cell lung cancer(NSCLC) remains the leading cause of cancer-related mortality worldwide. Since 2011, the U.S. Food and Drug Administration has approved over 30 new therapies for advanced NSCLC, primarily tyrosine kinase inhibitors and immune checkpoint inhibitors. Biologic age
ScientistとScience Exchangeとのご利用可能です。
